| 1 |
34910929 | Inhibition of cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions. | 2022 Jan 25 |
1 |
| 2 |
33060488 | Plasma Concentrations and Cardiovascular Effects of Citalopram Enantiomers After Oral Versus Infusion Citalopram Therapy in Dextromethorphan-Mephenytoin-Phenotyped Patients With Major Depression. | 2021 Jun 1 |
1 |
| 3 |
30902024 | Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine. | 2020 Feb |
2 |
| 4 |
31814297 | The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients. | 2020 May |
1 |
| 5 |
33115391 | Analysis of the Potential Association of Drug-Metabolizing Enzymes CYP2C9*3 and CYP2C19*3 Gene Variations With Type 2 Diabetes: A Case-Control Study. | 2020 |
1 |
| 6 |
33302490 | A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine. | 2020 Dec 8 |
1 |
| 7 |
30399481 | Investigation on drug-binding in heme pocket of CYP2C19 with UV-visible and resonance Raman spectroscopies. | 2019 Feb 15 |
4 |
| 8 |
29665549 | Combination of CYP2C19 genotype with non-genetic factors evoking phenoconversion improves phenotype prediction. | 2018 Jun |
1 |
| 9 |
27128896 | Inhibitory Effects of Aschantin on Cytochrome P450 and Uridine 5'-diphospho-glucuronosyltransferase Enzyme Activities in Human Liver Microsomes. | 2016 Apr 27 |
1 |
| 10 |
25845826 | Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic model. | 2015 Jun |
1 |
| 11 |
26021325 | The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles. | 2015 Aug |
1 |
| 12 |
23241944 | Human pharmacogenetic analysis in chimeric mice with 'humanized livers'. | 2013 Feb |
1 |
| 13 |
23318708 | Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. | 2013 |
1 |
| 14 |
22239545 | Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19. | 2012 Feb 9 |
1 |
| 15 |
22454664 | In Vitro Assessment of Cytochrome P450 2C19 Potential of Naoxintong. | 2012 |
1 |
| 16 |
22652334 | Assessment of drug-drug interactions caused by metabolism-dependent cytochrome P450 inhibition. | 2012 Jun 25 |
1 |
| 17 |
22943175 | In-vitro metabolism of glycyrrhetinic acid by human and rat liver microsomes and its interactions with six CYP substrates. | 2012 Oct |
1 |
| 18 |
21093571 | In vitro modulatory effects of Andrographis paniculata, Centella asiatica and Orthosiphon stamineus on cytochrome P450 2C19 (CYP2C19). | 2011 Jan 27 |
1 |
| 19 |
21325430 | Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation. | 2011 May |
2 |
| 20 |
20877236 | Effects of eupatilin and jaceosidin on cytochrome p450 enzyme activities in human liver microsomes. | 2010 Sep 16 |
1 |
| 21 |
19661214 | Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole. | 2009 Nov |
1 |
| 22 |
18071681 | Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity. | 2008 Apr |
3 |
| 23 |
18294333 | Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. | 2008 May |
1 |
| 24 |
18654768 | Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. | 2008 Dec |
1 |
| 25 |
17375979 | The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. | 2007 |
1 |
| 26 |
17521300 | Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. | 2007 Jun |
1 |
| 27 |
17600081 | High-throughput radiometric CYP2C19 inhibition assay using tritiated (S)-mephenytoin. | 2007 Oct |
2 |
| 28 |
17614006 | Relative roles of CYP2C19 and CYP3A4/5 in midazolam 1'-hydroxylation. | 2007 Jun |
2 |
| 29 |
16307177 | Novel mutations in the cytochrome P450 2C19 gene: a pitfall of the PCR-RFLP method for identifying a common mutation. | 2006 |
1 |
| 30 |
16679385 | Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. | 2006 Aug |
2 |
| 31 |
16719381 | CYP2C19-mediated (S)-mephenytoin 4'-hydroxylation assayed by high-performance liquid chromatography with radiometric detection. | 2006 |
1 |
| 32 |
16751594 | Cynomolgus monkey cytochrome P450 2C43: cDNA cloning, heterologous expression, purification and characterization. | 2006 May |
1 |
| 33 |
16922812 | Effects of individual ginsenosides, ginkgolides and flavonoids on CYP2C19 and CYP2D6 activity in human liver microsomes. | 2006 Sep |
2 |
| 34 |
15486075 | Interactions between CYP2C9 and CYP2C19 in reconstituted binary systems influence their catalytic activity: possible rationale for the inability of CYP2C19 to catalyze methoxychlor demethylation in human liver microsomes. | 2005 Jan |
1 |
| 35 |
15788366 | Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro. | 2005 Jan |
2 |
| 36 |
15043991 | Inhibition of cytochrome P450 activities by oleanolic acid and ursolic acid in human liver microsomes. | 2004 Apr 16 |
1 |
| 37 |
15145964 | The influence of St John's Wort on CYP2C19 activity with respect to genotype. | 2004 Jun |
1 |
| 38 |
15155554 | Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. | 2004 Jun |
1 |
| 39 |
15304427 | Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. | 2004 Nov |
1 |
| 40 |
15499174 | Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. | 2004 Apr |
1 |
| 41 |
12450547 | Stereoselective determination of the CYP2C19 probe drug mephenytoin in human urine by gas chromatography-mass spectrometry. | 2003 Jan 5 |
1 |
| 42 |
12597994 | Interaction of serum proteins with CYP isoforms in human liver microsomes: inhibitory effects of human and bovine albumin, alpha-globulins, alpha-1-acid glycoproteins and gamma-globulins on CYP2C19 and CYP2D6. | 2003 Mar 14 |
1 |
| 43 |
12637241 | mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates. | 2003 Mar |
2 |
| 44 |
12695344 | Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. | 2003 May |
1 |
| 45 |
12835613 | Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? | 2003 Jul |
1 |
| 46 |
12844133 | Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. | 2003 Jul |
1 |
| 47 |
12869636 | Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. | 2003 Aug |
1 |
| 48 |
12900870 | Capillary electrophoresis to assess drug metabolism induced in vitro using single CYP450 enzymes (Supersomes): application to the chiral metabolism of mephenytoin and methadone. | 2003 Aug |
4 |
| 49 |
12919185 | Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity. | 2003 Sep |
1 |
| 50 |
11907490 | Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men. | 2002 Mar |
1 |